The drug is the 16th original drug developed in Korea. But what makes Pyramax special is that it is Korea’s first home-grown drug with a wholly independent development process from pre-clinical to final phase clinical trials

Shin Poong Pharmaceutical Co., Ltd. (CEO Ryu Jei-Man) has signed an exclusive distribution agreement with Surgipharm Ltd. (Kenyan pharmaceutical distribution company) in Kenya for three years. According to the agreement, Surgipharm will supply to the private market in Kenya in May, and the quantity of treatments is approximately 10,000 patients.

In addition, Shin Poong has recently signed a distribution agreement with West African pharmaceutical distributor Tedis, for Pyramax distribution partnerships in 16 countries for three years, starting with 7 countries including, Cote d'Ivoire, Cameroon and Burkina Faso.

As penetrating into the private market sets the groundwork for listing as National treatment guideline in major African countries, which is estimated to bring sales in public market in the near future.

Currently, patients with malaria who need treatment of QAACT(Qualified-Assured Artemisinin combination therapy) are aided by public market, while 30% of those bear treatment cost without financial subsidy.

Pyramax has been primary candidate to be listed as national treatment guideline by undergoing discussion among national malaria control program, of which estimated date of listing will be different by countries